– John Shiver, Ph.D., and Tong-Ming Fu, M.D., Ph.D., Appointed as Chief Strategy Officer and Chief Scientific Officer, Respectively, of IGM Infectious.
By
Sun Apr 18 2021
A possible explanation for why many cancer drugs that kill tumor cells in mouse models won’t work in human trials has been found.
A possible explanation for why many cancer drugs that kill tumor cells in mouse models won’t work in human trials has been found by researchers with The University of Texas Health Science Center at Houston (UTHealth) School of Biomedical Informatics and McGovern Medical School.
The research was published today in Nature Communications.
In the study, investigators reported the extensive presence of mouse viruses in patient-derived xenografts (PDX). PDX models are developed by implanting human tumor tissues in immune-deficient mice, and are commonly used to help test and develop cancer drugs.
E-Mail
A possible explanation for why many cancer drugs that kill tumor cells in mouse models won t work in human trials has been found by researchers with The University of Texas Health Science Center at Houston (UTHealth) School of Biomedical Informatics and McGovern Medical School.
The research was published today in
Nature Communications.
In the study, investigators reported the extensive presence of mouse viruses in patient-derived xenografts (PDX). PDX models are developed by implanting human tumor tissues in immune-deficient mice, and are commonly used to help test and develop cancer drugs. What we found is that when you put a human tumor in a mouse, that tumor is not the same as the tumor that was in the cancer patient, said W. Jim Zheng, PhD, professor at the School of Biomedical Informatics and senior author on the study. The majority of tumors we tested were compromised by mouse viruses.